Stockholm, Sweden
21.05.17 - 24.05.17
Systems approaches to drug discovery, development and clinical usage
Join leading pharmaceutical scientists from around the world to discuss cutting-edge research and promising developments.
Stockholm, Sweden. An exciting venue in which the leading pharmaceutical scientists from across the globe will meet to discuss the medicines of the future. What will be the breakthroughs and the pitfalls? How can we meet the biggest challenges?
The International Pharmaceutical Federation is pleased to bring you the 6th PSWC, sponsored by many of the world’s leading pharmaceutical science and educational organisations.
What are the expectations?
- New scientific disciplines “Systems pharmacology” will develop as a new discipline of pharmaceutical science, focusing on the medicines-genetics interface and on biological network analysis as the scientific basis for drug action. This will enable efficacy and safety decisions, and will involve the development of novel concepts, biological models and biomarkers practice and we will be able to use “big data” for post-marketing drug evaluation. Systems therapeutics will trigger important discussions of the societal aspects of pre-emptive and preventive treatments.
- More information, improved safety In translational sciences, systems pharmacology models will cast light on pharmacokinetics and pharmacodynamics. This will fuel the optimisation of clinical trials in healthy subjects, patients, special populations and real-life populations. Similarly, systems toxicology models will be used for toxicity and safety evaluations in drug development.
- Precision treatments Systems therapeutic interventions are “precision treatments” that are tailored to individual patient characteristics, both with respect to drug choice and dosing regimen. They will change the field of formulation and manufacturing sciences. Interventions that require precise individualised dosing will impact on pharmaceutical formulation and processing. We will need to design new diagnostic tools and monitoring devices.
- Harnessing of “big” information In regulatory science, the systems approach will allow advanced modelling and simulation that will be used to enhance product safety and to improve the prediction from clinical evaluations. We will be able to harness diverse data through information sciences to improve health outcomes.
- Science-based practice The practice of science-based pharmacy will see major change. Individualised treatments will be a significant part of clinical practice and we will be able to use “big data” for post-marketing drug evaluation. Systems therapeutics will trigger important discussions of the societal aspects of pre-emptive and preventive treatments.
